Pensacola, Fla.-based Andrews Medicine, led by James Andrews, MD, is partnering with Houston-based Celltex Therapeutics to form a biotechnology company focused on stem cell research and sports medicine.
The new company will be called Andrews Celltex Biologics and will form a sports injury program, Celltex said in an Oct. 4 news release. The program will include a Celltex-sponsored FDA study associated with Mesenchymal stem cells in orthopedics, and Andrews Medicine will participate in research. The company aims to earn an FDA-approved biologic license for the Celltex product.
"I have always known that stem cells, when properly handled, can add value to already effective treatments of inflammatory conditions caused by injury or disease," Dr. Andrews said in the release. "I am delighted that the FDA has been working with Celltex for studying the safety and efficacy of this combination of Celltex-produced MSCs with traditional medical treatment of multiple sports injury indications. Our know-how and network of sports teams and physicians will add immediate value to our new joint company. I am convinced that Andrews Celltex Biologics will be a leader in this huge growth sector of health care coupled with regenerative medicine."